DSE 9912
Alternative Names: SEK 3001Latest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Sekisui
- Developer Dainippon Sumitomo Pharma; Sekisui
- Class Tocopherols; Vitamins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atopic dermatitis
Most Recent Events
- 08 Feb 2008 Discontinued - Phase-I for Atopic dermatitis in Japan (Topical)
- 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
- 28 May 2001 SEK 3001 is now called DSE 9912